Please ensure Javascript is enabled for purposes of website accessibility

AstraZeneca to Test Blood Cancer Drug for COVID-19 Treatment

By Eric Volkman – Apr 15, 2020 at 6:27PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The drug, Calquence, will be evaluated in a sprawling, two-phase trial.

Add another existing medication to the growing list of treatments that might be useful in the fight against the SARS-CoV-2 coronavirus, and the COVID-19 disease that can result from it. AstraZeneca (AZN -0.13%) announced it will initiate a clinical trial to determine if its Calquence blood cancer drug can help treat COVID-19.

Calquence has Food and Drug Administration (FDA) approval for two types of blood cancer. It works by blocking a protein that regulates the production of a certain type of inflammatory markers. This helps to limit the spread of mutating B cells in instances of blood cancer. It is thought that this could ease the exaggerated immune response seen in the advanced stages of COVID-19.

A medical professional using a microscope.

Image source: Getty Images.

"With this trial we are responding to the novel insights of the scientific community and hope to demonstrate that adding Calquence to best supportive care reduces the need to place patients on ventilators and improves their chances of survival," AstraZeneca wrote in its announcement.

The Calquence trial, christened CALAVI, will take place in the U.S. and in several European countries that weren't named. The U.S. component should open for enrollment within the next few days. It will be a two-part, randomized trial.

According to AstraZeneca, this will be the fastest clinical trial launch in company history.

Other top global pharmaceutical companies are putting approved medications that might combat aspects of COVID-19 into clinical trials at a rapid pace. Gilead is perhaps the best example, while Sanofi and Novartis, among numerous others, are also making such efforts.

AstraZeneca's shares declined by 1.3% on Wednesday, yet that was a slightly better performance than that of the broader stock market.

 

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$54.84 (-0.13%) $0.07
Sanofi Stock Quote
Sanofi
SNY
$38.02 (0.05%) $0.02
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$61.69 (-2.19%) $-1.38
Novartis AG Stock Quote
Novartis AG
NVS
$76.01 (-0.73%) $0.56

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.